NCT02238496 2023-05-25
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Phase 1 Completed
Clinical Trials
10 trialsNCT00590954 2020-10-19
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005794 2019-12-13
Perifosine in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT00422656 2017-12-26
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00776867 2017-08-01
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01049841 2017-03-10
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00431054 2016-02-19
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00053924 2015-07-23
Perifosine in Treating Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00054145 2015-07-23
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00873457 2013-05-27
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Duke University
Phase 2 Completed